Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102
PrECOG, LLC.
Noah Kornblum; Fengmin Zhao; Judith Manola; Paula Klein; Bhuvaneswari Ramaswamy; Adam Brufsky; Phillip J Stella; Brian Burnette; Melinda Telli; Della F Makower; Puneet Cheema; Cristina I Truica; Antonio C Wolff; Gamini S Soori; Barbara Haley; Timothy R Wassenaar; Lori J Goldstein; Kathy D Miller; Joseph A Sparano